Who to call at Hanmi Pharmaceutical Ltd, and when
Fundz watches for the moments Hanmi Pharmaceutical Ltd starts buying, and tells you who to reach.
- An alert the day Hanmi Pharmaceutical Ltd raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Hanmi Pharmaceutical Ltd, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Hanmi Pharmaceutical Ltd. With Fundz connected, it knows.
Contract Type
agreement
Description
Hanmi Pharm has entered into a global licensing and collaboration agreement with Gilead Sciences and Health Hope Pharma, granting Gilead exclusive rights to develop and commercialize Encequidar. The agreement includes upfront payments and potential royalties, with both companies collaborating on drug supply and technical know-how.
Quick answer
Hanmi Pharm Licenses Oral Drug Delivery Platform to Gilead for Encequidar Development. (September 29, 2025). Hanmi Pharmaceutical Ltd is based in South Korea.
- What agreement did Hanmi Pharmaceutical Ltd announce on September 29, 2025?
- Hanmi Pharm has entered into a global licensing and collaboration agreement with Gilead Sciences and Health Hope Pharma, granting Gilead exclusive rights to develop and commercialize Encequidar. The agreement includes upfront payments and potential royalties, with both companies collaborating on drug supply and technical know-how.
- What does Hanmi Pharmaceutical Ltd do?
- Hanmi Pharmaceutical Co. Ltd. is a biopharmaceutical company engaged in the research, development, manufacture, and marketing of innovative medicines with a focus on metabolic disorders, oncology, and rare diseases.
- Where is Hanmi Pharmaceutical Ltd based?
- Hanmi Pharmaceutical Ltd is based in South Korea.
Source: Fundz verified event record.
Related People
Hanmi Pharmaceutical Ltd signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.